Moderna, once the poster child of mRNA therapeutics, is under pressure from falling COVID vaccine revenues, government contract cancellations and investor demands to reduce spending, according to a detailed company profile. Management has responded with cost cuts and a narrowed pipeline focus while holding substantial cash reserves and advancing a cancer vaccine program. Separately, a research group presented data at the European Society for Medical Oncology showing that incidental receipt of COVID mRNA vaccines correlated with longer survival in cancer patients treated with checkpoint inhibitors; mouse work suggested generalized mRNA vaccination can prime anti‑tumor immunity. The finding is retrospective and requires randomized confirmation, but it has renewed interest in leveraging mRNA platforms beyond infectious disease. Together, the two items show mRNA’s commercial challenge in the near term and its scientific potential in oncology—factors that will shape investor appetite, corporate R&D prioritization, and government procurement strategies for platform technologies.